Loading...
Catabasis Pharmaceuticals, Inc.
CATB•NASDAQ
Healthcare
Biotechnology
$8.54
$-0.64(-6.97%)

Catabasis Pharmaceuticals, Inc. (CATB) Balance Sheet Analysis
Catabasis Pharmaceuticals, Inc. (CATB) manages its money wisely, with plenty of N/A and N/A to cover its bills. The company’s long-term debts are N/A, balanced by steady N/A. Shareholders’ stake in the business has shrunk. Overall, the numbers show a stable position, giving it room to invest, expand, or adapt. For investors, this paints a steady picture for the future.Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan